MGTX News and Press, MeiraGTx Holdings plc From 09/28/21

LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the virt...

LONDON and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced new data from subjects treated in the Phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RP...

LONDON and NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second quarter ended June 30, 2021 and provided an update on recent progress. ...

MeiraGTx (MGTX): Q1 GAAP EPS of -$0.54 misses by $0.11.Revenue of $4.6M (+9.3% Y/Y) beats by $3.17M.As of March 31, 2021, MeiraGTx had cash and cash equivalents of approximately $199.4 million, as well as approximately $12.0 million due in receivables from development partner Janssen Pharmace...

LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress. “...

LONDON and NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in multip...

LONDON and NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, and Stuart Naylor, Ph.D., chief de...

MeiraGTx (MGTX): FY GAAP EPS of -$1.54 beats by $0.14.Revenue of $15.56M (+17.1% Y/Y) misses by $1.6M.Press Release For further details see: MeiraGTx EPS beats by $0.14, misses on revenue

-  Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR -  Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Xerostomia -  Completed Build of Internal cGMP Plasmid and DNA Manufacturing Facility...

LONDON and NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barc...